Literature DB >> 11525387

Cisplatin: from DNA damage to cancer chemotherapy.

S M Cohen1, S J Lippard.   

Abstract

Cisplatin [cis-DDP, cis-diamminedichloroplatinum(II)] is a potent anticancer drug that has been used successfully to treat tumors of the head, neck, lungs, and genitourinary tract. The biological activity of cisplatin was discovered serendipitously more than 30 years ago, and since that time research efforts have focused on elucidating its mechanism of action. The present review provides a historical perspective of our attempts to understand this complex phenomenon and the results of recent work that guides our current activities in this field. Continued efforts to understand the mechanism of genotoxicity of cisplatin are expected to lead to the discovery of new drugs and combinations for the improvement of cancer chemotherapy.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11525387     DOI： 10.1016/s0079-6603(01)67026-0

Source DB:  PubMed          Journal:  Prog Nucleic Acid Res Mol Biol        ISSN： 0079-6603


  127 in total

Review 1.  A copper connection to the uptake of platinum anticancer drugs.

Authors:  John L Nitiss
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

2.  High-throughput genotoxicity assay identifies antioxidants as inducers of DNA damage response and cell death.

Authors:  Jennifer T Fox; Srilatha Sakamuru; Ruili Huang; Nedelina Teneva; Steven O Simmons; Menghang Xia; Raymond R Tice; Christopher P Austin; Kyungjae Myung
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-19       Impact factor: 11.205

3.  Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity.

Authors:  Anbarasi Kothandapani; Kathirvel Gopalakrishnan; Bhaskar Kahali; David Reisman; Steve M Patrick
Journal:  Exp Cell Res       Date:  2012-06-18       Impact factor: 3.905

4.  Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells.

Authors:  Amit Kumar Srivastava; Chunhua Han; Ran Zhao; Tiantian Cui; Yuntao Dai; Charlene Mao; Weiqiang Zhao; Xiaoli Zhang; Jianhua Yu; Qi-En Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

Review 5.  Developing better mouse models to study cisplatin-induced kidney injury.

Authors:  Cierra N Sharp; Leah J Siskind
Journal:  Am J Physiol Renal Physiol       Date:  2017-07-19

6.  Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.

Authors:  Priya Samuel; Ryan Charles Pink; Daniel Paul Caley; James Michael Stevenson Currie; Susan Ann Brooks; David Raul Francisco Carter
Journal:  Tumour Biol       Date:  2015-09-19

7.  Bifunctional cross-linking approaches for mass spectrometry-based investigation of nucleic acids and protein-nucleic acid assemblies.

Authors:  M Scalabrin; S M Dixit; M M Makshood; C E Krzemien; Daniele Fabris
Journal:  Methods       Date:  2018-05-10       Impact factor: 3.608

8.  Overexpression of DDB2 enhances the sensitivity of human ovarian cancer cells to cisplatin by augmenting cellular apoptosis.

Authors:  Bassant M Barakat; Qi-En Wang; Chunhua Han; Keisha Milum; De-Tao Yin; Qun Zhao; Gulzar Wani; El-Shaimaa A Arafa; Mohamed A El-Mahdy; Altaf A Wani
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

9.  PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis.

Authors:  Xiu Feng Hu; Jie Li; Scott Vandervalk; Zeping Wang; Nancy S Magnuson; Pei Xiang Xing
Journal:  J Clin Invest       Date:  2009-01-19       Impact factor: 14.808

10.  Phosphodiester-mediated reaction of cisplatin with guanine in oligodeoxyribonucleotides.

Authors:  Meghan A Campbell; Paul S Miller
Journal:  Biochemistry       Date:  2008-12-02       Impact factor: 3.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.